Soleus Capital Management L.P. Raises Stock Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Soleus Capital Management L.P. lifted its stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 97.3% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,102,833 shares of the company’s stock after buying an additional 1,036,999 shares during the quarter. Nurix Therapeutics comprises 2.5% of Soleus Capital Management L.P.’s portfolio, making the stock its 12th biggest holding. Soleus Capital Management L.P. owned 2.77% of Nurix Therapeutics worth $39,617,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. JPMorgan Chase & Co. grew its position in shares of Nurix Therapeutics by 85.2% during the third quarter. JPMorgan Chase & Co. now owns 68,148 shares of the company’s stock worth $1,531,000 after purchasing an additional 31,352 shares in the last quarter. Jump Financial LLC purchased a new stake in Nurix Therapeutics during the 4th quarter valued at approximately $1,406,000. Barclays PLC raised its position in shares of Nurix Therapeutics by 77.9% during the third quarter. Barclays PLC now owns 128,344 shares of the company’s stock valued at $2,884,000 after buying an additional 56,190 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its holdings in shares of Nurix Therapeutics by 42.7% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 789,222 shares of the company’s stock worth $14,869,000 after buying an additional 235,971 shares in the last quarter. Finally, Affinity Asset Advisors LLC lifted its holdings in shares of Nurix Therapeutics by 9.3% in the fourth quarter. Affinity Asset Advisors LLC now owns 940,083 shares of the company’s stock worth $17,711,000 after buying an additional 79,684 shares in the last quarter.

Nurix Therapeutics Price Performance

Nurix Therapeutics stock opened at $9.56 on Monday. The firm has a market capitalization of $728.82 million, a P/E ratio of -3.31 and a beta of 2.23. Nurix Therapeutics, Inc. has a 1-year low of $8.18 and a 1-year high of $29.56. The company’s 50-day moving average is $11.07 and its 200 day moving average is $16.80.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings results on Tuesday, April 8th. The company reported ($0.67) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.05. The firm had revenue of $18.45 million during the quarter, compared to analyst estimates of $12.78 million. Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. During the same period last year, the company earned ($0.76) EPS. Research analysts anticipate that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently weighed in on NRIX shares. Stifel Nicolaus cut their target price on shares of Nurix Therapeutics from $36.00 to $35.00 and set a “buy” rating for the company in a research note on Wednesday, April 9th. Needham & Company LLC restated a “buy” rating and set a $27.00 price objective on shares of Nurix Therapeutics in a research report on Tuesday, April 29th. Leerink Partnrs raised Nurix Therapeutics to a “hold” rating in a report on Monday, March 17th. Stephens reissued an “overweight” rating and set a $31.00 price target on shares of Nurix Therapeutics in a research note on Tuesday, January 21st. Finally, Wells Fargo & Company cut their price target on Nurix Therapeutics from $32.00 to $25.00 and set an “overweight” rating for the company in a report on Wednesday, April 9th. Three investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $30.44.

Insider Transactions at Nurix Therapeutics

In related news, CFO Houte Hans Van sold 6,198 shares of the firm’s stock in a transaction dated Friday, May 2nd. The shares were sold at an average price of $11.33, for a total value of $70,223.34. Following the transaction, the chief financial officer now owns 33,724 shares of the company’s stock, valued at $382,092.92. This trade represents a 15.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Gwenn Hansen sold 3,377 shares of Nurix Therapeutics stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $11.50, for a total transaction of $38,835.50. Following the sale, the insider now owns 61,516 shares of the company’s stock, valued at $707,434. The trade was a 5.20% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 17,838 shares of company stock worth $221,500. 7.40% of the stock is currently owned by insiders.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.